“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead’s option exercises to three ...
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2015 /PRNewswire/ -- Liquidia Technologies today announced that GlaxoSmithKline (GSK) has exercised its option under a Collaboration and Option Agreement signed ...
STARKVILLE, Miss.—Protection of personal healthcare information is a well-established right for patients, and technology underpins almost every aspect of healthcare operations. A recent cyber tabletop ...